AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Gabelli Healthcare & WellnessRx Trust Director Sells Shares in August and September.
ByAinvest
Tuesday, Dec 2, 2025 3:45 pm ET1min read
Gabelli Healthcare & WellnessRx Trust (GRX) has disclosed that Director VANEKRIS ANTHONIE C has made several transactions involving the sale of shares. On August 6, 2025, the Director sold 2000 shares at $9.12 per share, followed by the sale of 2000 shares at $9.2 per share on August 13, 2025. Further sales were made on September 4, 2025, with the Director selling 200 shares at $9.5 per share, and 800 shares at the same price on September 5, 2025. On October 8, 2025, the Director sold 1000 shares at $9.26 per share, and on October 9, 2025, another 1000 shares were sold at $9.27 per share. Finally, on October 13, 2025, the Director sold 1000 shares at $9.15 per share, and on October 14, 2025, 1000 shares were sold at $9.12 per share.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet